loss and end-stage renal failure) criteria were developed to standardize the definition and severity of acute kidney injury (AKI) but have not been previously used in brain-deceased donors. We applied the RIFLE classification to evaluate renal function changes in our donor pool, in an attempt to know its influence in transplant outcome. Methods. Data were collected from the renal transplant patient and the intensive care unit brain-dead donors prospectively maintained databases of our hospital. Risk was defined when creatinine increased ×1.5, injury when it increased ×2 and failure when last creatinine increased ×3 with respect to admission-day creatinine.
loss and end-stage renal failure) criteria were developed to standardize the definition and severity of acute kidney injury (AKI) but have not been previously used in brain-deceased donors. We applied the RIFLE classification to evaluate renal function changes in our donor pool, in an attempt to know its influence in transplant outcome. Methods. Data were collected from the renal transplant patient and the intensive care unit brain-dead donors prospectively maintained databases of our hospital. Risk was defined when creatinine increased ×1.5, injury when it increased ×2 and failure when last creatinine increased ×3 with respect to admission-day creatinine.
Results. From 176 donors, 10.8% suffered AKI and 7.9% were included in 'risk', 2.3% in 'injury' and 0.6% in 'failure' categories. There were no significant differences between AKI and non-AKI groups in donor and intensive care management variables, except in last-day creatinine. First-day urine volumes were lower (P=0.043) and delayed graft function rates were higher (P = 0.013) in the AKI group than in the non-AKI group recipients. Graft survival and other outcome variables were not different between
Introduction
There is an increasing disparity between demand for kidney transplant and availability of suitable organs, causing the number of patients awaiting renal transplantation to increase more than twofold in recent years [1] . The limited supply of deceased donors for renal transplantation led to considering alternative strategies for making more organs available. Among the strategies employed to expand the donor pool are the use of organs from older donors and/ or from donors with a history of hypertension and diabetes and those with elevated serum creatinine [2, 3] . In the early 2000s, the concept of expanded criteria donors (ECD) was defined in order to include those older donors with hypertension and/or diabetes and/or renal dysfunction, who are expected to produce allografts at higher risk of graft lost than 'normal donors', but adequate enough to be used [4] . However, nowadays there are no unequivocal definitions of what are adequate or marginal donors. Differences in acceptance or refusal criteria between centers allow that one-center-discarded kidneys provide satisfactory survival rates in other centers that consider them acceptable for transplantation. After impaired donor hemodynamics, the second (22%) most frequently alleged reason for refusal is abnormal pre-harvesting serum creatinine [2] . Donor renal dysfunction is usually a reversible condition, caused by hypoxic-ischaemic and nephrotoxic insults, such as drug overdose and myoglobinuria [5, 6] . Several studies have analysed how donor terminal creatinine influences the outcome of kidney transplantation [2] [3] [4] 7, 8] . Port et al. found that serum creatinine >1.5mg/dl was associated with a 10% higher risk of graft failure, while Ugarte et al. showed that kidneys with a final donor creatinine ≥2.0mg/dl performed as well as kidneys from donors with a normal terminal creatinine with respect to graft and patient survival and renal function [4, 7] . These studies demonstrated that kidneys from donors with high final creatinine cannot be discarded as unacceptable for transplantation only based on this criterion. On the other hand, few studies and with a low number of patients included have reported the influence of a donor deteriorating renal function in the outcome of kidney transplantation [5, 6, 9] . Kidneys from donors with rising creatinine can be used safely under certain conditions, providing comparable survival and function with respect to kidneys from donors without acute renal failure (ARF) and with only a higher risk of suffering delayed graft function (DGF) [5, 6] .
As the scientific community needed a universally recognized definition of acute kidney injury (AKI), the Acute Dialysis Quality Initiative (ADQI) Working Group developed the RIFLE (risk, injury, failure, loss and end-stage renal failure) criteria. The RIFLE criteria provide a graded and uniform definition and classification of AKI severity, with the primary aim of reliably identifying different stages of disease progression. While the 'risk' group has a high sensitivity to detect AKI, the 'failure' group has a high specificity [10] . This classification was intended to standardize the definition and severity of AKI, rather than be a tool to predict mortality and renal outcome [11] , although further studies have demonstrated its reliability to forecast death [11] [12] [13] [14] [15] and renal outcome [13, 15] . The ADQI group suggested that the RIFLE classification must be tested in different data sets [10] , and a recent survey has shown that the RIFLE classification is being used more commonly in Europe [16] . In order to improve our approach to AKI in donors, we retrospectively applied the RIFLE classification to evaluate renal function changes in our donor pool, trying to standardize and detect subtle deterioration of renal function and to know the risk factors for AKI in donors and its influence in transplant outcome.
Materials and methods
Data were collected from the prospectively maintained database of all renal transplant patients and the prospectively maintained database of all brain-deceased donors of the intensive care unit (ICU) in our hospital. Both databases were matched anonymously by the hospital number of the donor. Only donors with creatinine collected on admission day and the last day before donation were analysed. Recipients with vascular graft thrombosis were also excluded. From 1994 to 2006, 176 deceased donors and 312 kidney recipients were selected. All kidneys were preserved by simple ice preservation. The study was conducted according to the guidelines of the Declaration of Helsinki and was approved by the ethical committee of our hospital.
The following donor and intensive care management variables were included: age, gender, history and years of hypertension, history of diabetes, death cause, admission and terminal creatinine, last day 24-h urine volume, Acute Physiology and Chronic Health Evaluation (APACHE) II score at ICU admission, days in ICU, hypotension and length in minutes, number of transfusions received and central venous pressure. Recipient and transplant procedure factors analysed were age, gender, transplant number, peak panel-reactive antibodies (PRA), body mass index, endstage renal disease (ESRD) cause, history of diabetes, type of renal replacement therapy, immunosuppressive drugs, cold ischaemia time and mismatches. Kidney transplant outcome variables included were DGF, number of dialysis performed after transplantation, creatinine on days 1, 2, 5 and at months 6 and 12, creatinine reduction ratio on day 2, first-day urine volume, Doppler resistive index at day 2, acute rejection and graft survival. DGF was defined as a dialysis requirement during the first week post-transplant.
The RIFLE criteria were used to classify AKI into three categories using serum creatinine changes to assess the severity of kidney damage. Risk was defined when creatinine increased ×1.5, injury when it increased ×2 and failure when last creatinine increased ×3 with respect to admission-day creatinine [10] . Our practice is to accept kidneys with high terminal creatinine only if the clinical impression suggests a reversible lesion. Obviously, patients with the two clinical outcome categories (loss and end-stage kidney disease) were not accepted as kidney donors. AKI was defined in the donors included in the risk, injury or failure categories.
Kidney recipients received different immunosuppressive drugs during the period of the study. Most of them (95.1%) were under an anticalcineurin drug. Also, a majority of patients (87.4%) received a purin-synthesis inhibitor. Sirolimus was used in 13.3% of recipients. All patients received steroids and only 6.9% induction therapy with polyclonal or monoclonal antibodies.
Statistical analysis was performed using SPSS 8.0 (SPSS, Inc., Chicago, IL, US). Comparison between AKI and non-AKI was analysed by using Student's t-test for numerical values and chi-square test for categorical data. Comparison between RIFLE groups and non-AKI group was performed by Kruskal-Wallis test for numerical values and chi-square test for categorical data. Graft survival probability was calculated using Kaplan-Meier estimate. A P value of <5% was reported as statistically significant.
Results

Donor and intensive care risk factors for AKI
In all, 19 (10.8%) donors suffered AKI. Fourteen (7.9%) donors were included in 'risk', four (2.3%) in 'injury' and one (0.6%) in 'failure' category of AKI. Donor characteristics and intensive care management variables related with AKI and RIFLE are shown in Table 1 . There were no significant differences between AKI and risk groups and the non-AKI group in donor and intensive care management variables, except in last creatinine. Patients in the injury group were significantly older, had suffered hypertension for longer, their APACHE severity scores were worse and showed higher last creatinine levels than patients in the non-AKI group. Furthermore, injury patients showed a trend toward being more frequently hypertensive, staying longer in the ICU and toward having suffered more hypotensive episodes and for a longer time compared with the non-AKI group, although without reaching statistical significance. Also, APACHE score and the hypotension length were higher in injury patients than in risk patients.
Characteristics of the transplant recipients according to AKI and RIFLE
Recipient and transplant procedure characteristics are shown in Table 2 . In all, 279 recipients received a kidney from a donor without AKI, and 33 (10.5%) patients were transplanted from a donor with AKI. Taking into account the donor RIFLE category, 24 recipients received a kidney from the risk group, 7 from the injury group and 2 from the failure category. Recipients of donors with AKI received their second or third graft more frequently than those recipients of kidneys without AKI. The remaining recipient and transplant variables studied were not significant. Also, there was no difference in immunosuppressive therapy (data not shown).
AKI and RIFLE in donor influence transplant outcome
Graft outcome, including renal function throughout the first year, and graft survival are reported in Table 3 . First-day urine volumes were lower (P = 0.043) and DGF rate was higher (P = 0.013) in the AKI group than in the non-AKI group recipients. As can be seen in the graph (Figure 1 ), initial renal function (1st, 2nd and 5th day creatinine) was slightly better in the non-AKI group, although without statistical significance. Similarly, 5th day creatinine and 2nd day creatinine were higher in the risk and injury groups, re- 
Discussion
According to our results,~10% of brain-deceased donors suffer AKI, and 10% of recipients are transplanted with a kidney suffering AKI. Most of them can be included in the risk category for ADQI classification. Only a few donors were included in injury and failure groups. As expected, these percentages are lower than those previously reported by Sohrabi et al. in donors after cardiac death. In this high risk group, up to 18% of recipients received kidneys from donors with AKI according to the RIFLE criteria, a majority of them (16%) being included in the risk category and none of them in the failure group [9] . To our knowledge, our study is the first report that uses RIFLE criteria to analyse the kidney damage that occurs in brain-deceased donors. Most previously published papers have focused only on the last renal function of the donor and not on its change during intensive care management [4, 7, 8] . Using the data of 29 068 patients from the Scientific Registry of Transplant Recipients, Port et al. reported that 12% of donors have a terminal creatinine >1.5mg/dl [4] . Only one study did research into ARF of deceased donors but without using the RIFLE category to classify AKI [6] . RIFLE is an internationally accepted classification that can be a useful tool to standardize and quantify the renal damage in AKI, even in the donor setting. In this sense, it could be possible to discard or accept donors with AKI by applying the RIFLE classification scheme. Since the ADQI report, several studies have analysed the incidence and influence of AKI using the RIFLE classification. The largest study by Bagshaw et al. evaluated 120 123 patients admitted to an ICU, and they found that AKI occurred in 36.1% of patients, including 16.3% in risk, 13.6% in injury and 6.3% in the failure groups [12] . AKI rate was similar (35.8%, RIFLE 17.2%, injury 11% and failure 7.6%) in a UK and German study with near 42 000 patients in ICU [17] . In ICU, global AKI incidence varies between 10.8 and 67.2% [11] . This discrepancy can be explained by the different patient characteristics in each ICU, such as admission cause and severity. Obviously, our sample of brain-deceased kidney donors is not representative of all patients admitted in ICU and shows a lower AKI incidence. More than 85% of our donors suffered traumatic head injury or stroke as a cause of death, while in an extensive ICU cohort, only 7.7% of patients suffered trauma and 9.3% a neurologic problem as primary diagnosis [12] . Moreover, a patient is discarded as a possible donor when having sepsis or suffering certain comorbid conditions such as malignancies that are frequent in ICU patients.
In our study, neither donor characteristic nor intensive care management variables were related with a higher risk of suffering AKI. Only the lengths of stay in ICU and of low blood pressure were longer in those patients that will develop AKI but without statistical significance. By contrast, several variables were significantly related with injury (donor age, years from diagnosis of hypertension and APACHE II) or showed a trend to be higher in injury pa- tients without reaching statistical significance (hypertension incidence, hypotensive episodes and days in ICU). All these variables are well known risk factors for developing kidney damage. Previous ICU reports have shown that the odds of developing AKI were higher in older patients and those with higher severity scores measured by APACHE II. Besides, a more advanced RIFLE category was associated with a greater severity of illness estimated by APACHE II score, lower mean arterial pressures and higher doses of vasopressor drugs [12, 13, 17] . For instance, APACHE II score increases progressively from non-AKI patients (mean 14.7), to risk (18.1), injury (21.8) and failure (25.6) categories [12] . In a population-based study including not only patients in ICU, hypovolemia, the duration of hospital stay, age and the number of comorbid conditions were related with the development of AKI and with the RIFLE category [15] . Since the age and comorbidity of the general population and, hence, of possible donors will increase over the next years, we could expect that these donors will be in a higher risk for AKI and worse RIFLE category than nowadays. Although RIFLE criteria were developed as a tool to have a standard definition and classification of AKI and not to provide prognosis information, they have also been used as a renal function prediction system [13, 15] . Usually AKI is fully reversible, but the renal repair process can be incomplete and result in maintained decreased kidney function. We have found that recipients of kidneys from donors with AKI have a worse early graft outcome, as they have a higher risk for DGF, a lower first-day urine volume and tend to show higher serum creatinine during the first 5 days after transplantation. By contrast, AKI in donors did not influence either graft function from the sixth month or graft survival. These findings are similar to those previously reported in non-transplant patients with AKI. In nontransplant patients, the natural long-term functional outcome of AKI secondary to acute tubular necrosis has two phases. During the first of these, which can last over a year, renal function improved progressively. During the second phase, renal function remained stable or slightly decreased over the next years [18] . Abosaif et al. found that serum creatinine levels at the first and sixth months were no different in ICU patients between AKI and RI-FLE groups and non-AKI patients [13] .
In non-transplant patients, a majority of patients (92.5%) with AKI have full recovery of renal function, reflecting the good functional prognosis of acute tubular injury [15] . However, the renal repair process can also be incomplete and result in chronically decreased kidney function [19] . As demonstrated in a recent meta-analysis, recovery of renal function after AKI is~28% less likely to occur when the patient is older than 65years [19] . Together with age, comorbidity is also an independent predictor of renal function recovery [18] . Usually donors are younger and healthier than people included in AKI studies, and the long-term renal function prognosis of their recipients must be better. The increasing age and comorbidities of donors can promote not only AKI in them but also a worse recovery of renal function after transplantation.
In order to assess the potential viability of a donor with renal dysfunction, it is important to know whether donor renal failure is acute or chronic [3] . Initial transplant studies have focused only on terminal serum creatinine to evaluate kidney function. Most of these reports have reached conclusions similar to ours: kidneys from donors with high terminal serum creatinine have a higher rate of DGF after transplantation and equal or slightly worse graft survival [2, 4, 7] . Ugarte et al. reported that donors with a final creatinine ≥2 performed as well as kidneys from donors with a normal terminal creatinine with respect to graft survival but with a tendency to suffer more DGF [7] . Dahmane et al. found that kidneys refused by two or more centers developed more DGF (63 vs 32%, P<0.0001) but the same 5-year survival (70.4 vs 76.7%, P=0.129) [2] . In the seminal study by Port et al. defining ECD, terminal serum creatinine >1.5mg/dl was associated with a 10% higher risk of graft failure (Relative Risk=1.10, P=0.04), while other levels of serum creatinine (>1.3 and >2.0mg/dl) were not useful for determining risk of graft failure [4] . These previous reports could not distinguish if the kidney damage was acute or chronic.
Few reports have analysed the influence of donor ARF in transplant outcome [5, 6, 9] . Kumar et al. compared 55 kidneys from donors with severe ARF (defined by a 2-fold increase in serum creatinine with a baseline level <1.5mg/dl) with recipients of standard criteria donors (SCD) and ECD. DGF was observed more frequently in recipients of ARF kidneys than in SCD recipients (88 vs 48%), but 3-year graft survival and sixth-month creatinine were no different (90 vs 89%, 1.6 vs 1.5mg/dl). According to the RIFLE criteria, all Kumar's ARF kidneys could be included in the injury category of AKI [6] . RIFLE criteria were used for the first time in donors by Sohrabi et al. to classify 49 transplant recipients from donors after cardiac death. Only nine patients showed AKI. Their 1-year glomerular filtration rate was no different from non-AKI recipients, but the rate of DGF was higher (47.5 vs 25%) without statistical significance [9] . These previous results and ours confirm that kidneys from possible donors with AKI must not be discarded only based on abnormal renal function. However, the severity of renal dysfunction must be taken into account, as it can influence graft outcome too. A majority of our patients were included in the risk group, while only two patients were in the failure group. The RIFLE classification was designed to have a high sensitivity in the risk group and a high specificity in the failure group [14] . In this sense, the high rate of risk patients in our AKI group might reflect an over-diagnosis of AKI in donors with trivial kidney damage which will not have any influence on graft outcome. Studies including a higher percentage of injury and failure donors are needed to know their significance more accurately.
This study is limited by several issues. Firstly, although the data were collected in prospectively maintained databases, the study is retrospective. We could not therefore know the graft outcome of all kidneys of donors suffering AKI, only of the kidneys that were transplanted. Our conclusion cannot be that we must use all the kidneys of AKI donors, but it must be that we cannot exclude kidneys only based on AKI donor criteria. Other causes of kidney refusal are impaired donor haemodynamics, advanced age and donor atheroma, but abnormal pre-harvesting serum creatinine is the refusal reason in up to 22% of cases [2] . Acceptance of AKI donors can increase the kidney pool significantly, but prospective studies must prove that they are adequate kidneys for donation.
Secondly, the most important limitation of our study was the low number of patients included, mainly in the injury and failure groups. As pointed out above, these categories are more specific of AKI than risk. The high rate of risk patients in our AKI group might reflect an over-diagnosis of AKI in donors with trivial kidney damage. In order to have a better knowledge of both risk factors for AKI and the influence of AKI over graft outcome, it seems convenient to include more patients from the injury and failure groups in further studies.
Thirdly, we used the RIFLE classification without taking urine volume into account. In the database, we collected only 24-h urine output from the last day before donation, and neither 6-h nor 12-h volume. For this reason, we were unable to classify the patients according to this criterion. As shown by Ricci et al. in their systematic review, more than onethird of studies using RIFLE to classify AKI did not use the urine output criteria, due to the difficulty in obtaining accurate records. However, the urine output criteria for risk, injury and failure do not seem well balanced with the respective creatinine criteria, the former being more sensitive. The RIFLE class has a higher impact on mortality among studies in which urine criteria were not used than used [11] . By this token, the RIFLE classification without urine criteria can be more specific to define AKI severity.
Conclusion
In order to increase the donor pool, it is necessary to minimize organ refusal. A significant number of kidneys are discarded due to elevations of serum creatinine, although it has been demonstrated that kidneys from donors with acute renal damage provide comparable graft outcomes with respect to organs without damage. More than 10% of brain-deceased donors can suffer AKI and the percentage can be higher in cardiac deceased donors.
As these grafts perform adequately, the development of AKI in donors cannot be an isolated criterion to discard kidney donation.
RIFLE criteria are useful for discriminating clinical relevant outcomes of non-transplant patients and can also be used to define AKI in donors. RIFLE is feasible in order to accurately diagnose AKI in kidney donors and in order to uniformly stratify epidemiology of kidney donors with renal dysfunction. Recipients from RIFLE-defined AKI and non-AKI donors have significantly different early outcomes but similar long-term graft survival and renal function. Due to the low number of donors with severe AKI forms included in our study, definitive conclusions about the outcome of grafts from donors with injury or failure cannot be drawn. A wider utilization of the RIFLE classification in the clinical kidney donation field would make further studies possible including a greater number of patients in the injury and failure groups in order to precisely know their influence on graft outcome.
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